Advertisement
Advertisement
U.S. Markets close in 2 hrs 16 mins
Advertisement
Advertisement
Advertisement
Advertisement

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.19+0.10 (+1.24%)
As of 01:43PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.09
Open8.15
Bid8.15 x 800
Ask8.16 x 900
Day's Range8.10 - 8.57
52 Week Range7.55 - 20.35
Volume324,801
Avg. Volume445,798
Market Cap269.856M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.27
  • GlobeNewswire

    Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

    NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019 clinical update is expected by year-end 2022NKX101 clinical update is expected in first half of 2023Presentations at SITC 2022 on enhanced anti-tumor activity of NKX019 when combined with CD20-targeted monoclonal antibodies in preclinical models, and next-generation commercial-scale NK cell manufact

  • GlobeNewswire

    Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

    Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy from a Selected Single Donor SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell ther

  • GlobeNewswire

    Nkarta to Participate at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: Cowen IO Next SummitNovember 11, 202210:40 a.m. ET – fireside chat Stifel Healthcare ConferenceNovember 15, 20228:35 a.m. ET – fireside chat Evercore ISI HealthCONx ConferenceNovember 29, 202211:20 a.m. ET – fireside chat A simultan

Advertisement
Advertisement